Analyst Presentation: Interim results for the six months ended 30 June 2018
13 September 2018
Analyst conference call: Oxford BioMedica and Axovant Sciences enter into a $842.5 Million Exclusive Worldwide Licence Agreement for Oxford Biomedica-102 for the Treatment of Parkinson’s Disease
6 June 2018
Analyst conference call: Preliminary results for the year ended 31 December 2017
15 March 2018
Analyst conference call: Oxford BioMedica and Bioverativ Collaboration
15 February 2018
Analyst Presentation: Interim results for the six months ended 30 June 2017
17 August 2017
